SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SAN

73.045

-1.43%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

Home・Lista de Ações・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

79.55 1.66

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

79.55

Máximo

79.8

Indicadores-chave
By Trading Economics
Rendimento	-33M 43M
Vendas	7.9M 218M
P/E Médio do Setor	33.502 49.8
EPS	0.834
Margem de lucro	19.539
Funcionários	1,950
EBITDA	-21M 63M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+32.46% upside

Dividendos
By Dow Jones
Próximos Ganhos	23 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	84M 4.1B
Abertura anterior	77.89
Fecho anterior	79.55

Sentimento de Notícias

By Acuity

50%

159 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

51.1 / N/A Suporte e Resistência

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 de mai. de 2026, 23:38 UTC

Conversa de Mercado

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 de mai. de 2026, 23:14 UTC

Conversa de Mercado

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 de mai. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 de mai. de 2026, 10:21 UTC

Ganhos

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 de mai. de 2026, 06:05 UTC

Ganhos

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Still Going Strong -- Barrons.com

8 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 20:49 UTC

Ganhos

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 de mai. de 2026, 20:25 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Net $115M

8 de mai. de 2026, 19:20 UTC

Conversa de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 de mai. de 2026, 19:18 UTC

Ganhos

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 de mai. de 2026, 19:16 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:08 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:05 UTC

Ganhos

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 de mai. de 2026, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 de mai. de 2026, 18:51 UTC

Ganhos

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 de mai. de 2026, 18:49 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 18:41 UTC

Ganhos

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 de mai. de 2026, 17:14 UTC

Ganhos

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 de mai. de 2026, 17:04 UTC

Conversa de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

32.46% parte superior

Previsão para 12 meses

Média 83.25 EUR 32.46%

Máximo 83.5 EUR

Mínimo 83 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentimento

By Acuity

159 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.